CRISPR/Cas9 in Gastrointestinal Malignancies.
CRISPR/cas9
cancer of the biliary tract
colorectal cancer
esophageal cancer
gastrointestinal cancer
hepatocellular cancer
pancreatic cancer
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
06
2021
accepted:
28
10
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
17
12
2021
Statut:
epublish
Résumé
Gastrointestinal (GI) cancers such as colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EG), pancreatic duct adenocarcinoma (PDAC) or hepatocellular cancer (HCC) belong to the most commonly diagnosed types of cancer and are among the most frequent causes of cancer related death worldwide. Most types of GI cancer develop in a stepwise fashion with the occurrence of various driver mutations during tumor progression. Understanding the precise function of mutations driving GI cancer development has been regarded as a prerequisite for an improved clinical management of GI malignancies. During recent years, CRISPR/Cas9 has developed into a powerful tool for genome editing in cancer research by knocking in and knocking out even multiple genes at the same time. Within this review, we discuss recent applications for CRISPR/Cas9-based genome editing in GI cancer research including CRC, GC, EG, PDAC and HCC. These applications include functional studies of candidate genes in cancer cell lines or organoids
Identifiants
pubmed: 34912798
doi: 10.3389/fcell.2021.727217
pii: 727217
pmc: PMC8667614
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
727217Informations de copyright
Copyright © 2021 Jefremow, Neurath and Waldner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Biotechnol. 2016 Sep 08;34(9):933-941
pubmed: 27606440
Nat Biotechnol. 2017 Jun;35(6):569-576
pubmed: 28459449
Cancers (Basel). 2019 Nov 29;11(12):
pubmed: 31795490
Science. 2007 Mar 23;315(5819):1709-12
pubmed: 17379808
Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1491-1496
pubmed: 29282854
Mol Ther Methods Clin Dev. 2019 Mar 15;13:359-370
pubmed: 30989086
Oncogene. 2021 Jan;40(1):177-188
pubmed: 33110234
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Hepatol. 2020 Jul;73(1):170-185
pubmed: 32171892
J Bacteriol. 1987 Dec;169(12):5429-33
pubmed: 3316184
Cancer Res. 2017 Nov 15;77(22):6330-6339
pubmed: 28954733
Hepatology. 2016 Apr;63(4):1213-26
pubmed: 26683595
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Physiol Pharmacol. 2020 Oct;71(5):
pubmed: 33571964
Microbiology (Reading). 2005 Aug;151(Pt 8):2551-2561
pubmed: 16079334
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Am J Cancer Res. 2019 Jun 01;9(6):1183-1200
pubmed: 31285951
Cancer Discov. 2016 Jul;6(7):727-39
pubmed: 27231123
Lab Anim Res. 2018 Dec;34(4):257-263
pubmed: 30671113
Eur J Cancer. 2018 Apr;93:10-18
pubmed: 29433054
Cell Stem Cell. 2020 May 7;26(5):782-792.e7
pubmed: 32348727
Lab Invest. 2018 Jun;98(6):734-744
pubmed: 29467456
Oncotarget. 2017 Feb 14;8(7):11950-11962
pubmed: 28060762
Carcinogenesis. 2020 Jul 10;41(6):734-742
pubmed: 31665232
Gastroenterology. 2020 Sep;159(3):1019-1035.e22
pubmed: 32446697
Hepatology. 2020 Sep;72(3):982-996
pubmed: 31879968
Microbiology (Reading). 2005 Mar;151(Pt 3):653-663
pubmed: 15758212
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Nat Commun. 2019 Oct 15;10(1):4681
pubmed: 31615983
J Cancer Res Clin Oncol. 2018 Jun;144(6):1025-1035
pubmed: 29532228
Gastroenterology. 2015 Oct;149(5):1153-1162.e3
pubmed: 26073375
Mol Cancer Ther. 2020 Nov;19(11):2267-2277
pubmed: 32879054
Hepatology. 2019 Jan;69(1):376-393
pubmed: 30033593
Cancers (Basel). 2020 Apr 29;12(5):
pubmed: 32365487
Gastroenterology. 2019 Feb;156(3):562-576
pubmed: 30476497
Gut. 2017 Sep;66(9):1645-1656
pubmed: 27329244
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Exp Clin Cancer Res. 2017 Jan 9;36(1):8
pubmed: 28069043
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Oncogenesis. 2019 May 10;8(5):33
pubmed: 31076567
Prog Mol Biol Transl Sci. 2016;144:241-275
pubmed: 27865459
Oncogenesis. 2019 Oct 22;8(11):61
pubmed: 31641101
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Cell Stem Cell. 2018 Mar 1;22(3):454-467.e6
pubmed: 29337182
Onco Targets Ther. 2019 Nov 18;12:9899-9913
pubmed: 31819487
Nature. 2015 May 7;521(7550):43-7
pubmed: 25924068
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
Front Med (Lausanne). 2021 Mar 03;8:649896
pubmed: 33748164
World J Gastrointest Oncol. 2014 May 15;6(5):112-20
pubmed: 24834141
Biomed Pharmacother. 2019 Mar;111:76-85
pubmed: 30576937
J Mol Evol. 2005 Feb;60(2):174-82
pubmed: 15791728
Cancer Discov. 2021 Jun;11(6):1562-1581
pubmed: 33451982
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
J Gastrointest Oncol. 2012 Sep;3(3):153-73
pubmed: 22943008
Semin Cancer Biol. 2019 Apr;55:106-119
pubmed: 29673923
Nat Commun. 2019 Dec 2;10(1):5492
pubmed: 31792210
Gastroenterology. 2017 Dec;153(6):1662-1673.e10
pubmed: 28923495
Onco Targets Ther. 2020 Jan 06;13:17-29
pubmed: 32021251
Oncotarget. 2016 Mar 22;7(12):14188-98
pubmed: 26893358
Nat Rev Cancer. 2015 Jul;15(7):387-95
pubmed: 26040603
Gastroenterology. 2019 Jan;156(1):130-144.e10
pubmed: 30268789
Science. 2014 Nov 28;346(6213):1258096
pubmed: 25430774
Cell Rep. 2021 Jan 26;34(4):108676
pubmed: 33503428
Neoplasia. 2017 Mar;19(3):154-164
pubmed: 28147304
Cell Stem Cell. 2020 Mar 5;26(3):431-440.e8
pubmed: 32142663
Nat Med. 2015 Mar;21(3):256-62
pubmed: 25706875
Cell. 2018 Aug 9;174(4):856-869.e17
pubmed: 30096312
Oncotarget. 2018 Jun 26;9(49):29220-29232
pubmed: 30018747
Front Cell Dev Biol. 2019 Oct 18;7:239
pubmed: 31681770
Front Pharmacol. 2018 Oct 01;9:1118
pubmed: 30327605